Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Oseltamivir Phosphate Oral Suspension
NCT05297968Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oseltamivir in influenza (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration up to 1 year, Area under the plasma concentration versus time curve from time zero to the last measurable concentration up to 1 year and 2 more. Started May 2021; status: completed.
02
Drugs
oseltamivir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05297968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297968.